Background Limited effectiveness of therapeutic agents targeting epidermal growth factor
receptor (EGFR) in clinical trials using unselected ovarian cancer patients has prompted …

Epithelial ovarian cancer (EOC) remains one of the leading causes of cancer-related deaths
among women worldwide. Receptor tyrosine kinases (RTKs) have long been sought as …

Background The prognostic role of human epidermal growth factor receptor 2 (HER2) in
ovarian cancer has been investigated in previous studies, but the results remain …

Ovarian cancer is one of the most lethal gynaecological malignancies worldwide. Despite
high success rates following first time treatment, this heterogenous disease is prone to …

Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for
more deaths than any other gynecological malignancy. Despite some improvement in …

Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and tumoural
heterogeneity (TH) has been blamed for treatment failure. The genomic and epigenomic …

Ovarian cancer is the second most lethal gynecological cancer worldwide and while most
patients respond to initial therapy, they often relapse with resistant disease. Human …

Background The disruption of E-cadherin-mediated adhesion is considered an important
driver of tumor progression. Nevertheless, numerous studies have demonstrated that E …

Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that has been approved for
metastatic non-small cell lung cancer and highly aggressive pancreatic cancer. Although …

We analyzed variations in the epidermal growth factor receptor (EGFR) gene and 5′‐
upstream region to identify potential molecular predictors of treatment response in primary …